Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2026 to 2040 of 9004 results

  1. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

    Awaiting development Reference number: GID-TA10715 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gout

    Awaiting development Reference number: GID-QS10100 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374]

    Awaiting development Reference number: GID-TA12014 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [TSID12377]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  13. Non-Invasive Fat Reduction and Body Contouring

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development

  15. Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids

    In development Reference number: GID-HTG10470 Expected publication date: TBC

    HealthTech guidance
    In development